Brain inflammation may play an important role in the pathophysiology of early brain injury after subarachnoid hemorrhage (SAH). Our aim was to demonstrate brain inflammation development and to determine whether isoflurane, a clinically available volatile anesthetic agent, prevents brain inflammation after SAH. This study used 162 8-week-old male CD-1 mice. We induced SAH with endovascular perforation in mice and randomly assigned animals to sham-operated (n = 21), SAH + vehicle-air (n = 35) and SAH + 2% isoflurane (n = 31). In addition to the evaluation of brain injury (neurological scores, brain edema and Evans blue dye extravasation), ) and sphingosine-1-phosphate receptor-1/3 antagonist (VPC23019) were used to block isoflurane's effects (n = 22, each). SAH caused early brain injury, which was associated with inflammation so that all evaluated markers of inflammation were increased. Isoflurane significantly inhibited both brain injury (P b 0.001, respectively) and inflammation (myeloperoxidase, P = 0.022; interleukin-1β, P = 0.002; TNF-α, P = 0.015; P-selectin, P = 0.010; ICAM-1, P = 0.016; p-JNK, P b 0.001; cyclooxygenase-2, P = 0.003, respectively). This beneficial effect of isoflurane was abolished with DMS and VPC23019. Isoflurane may suppress post-SAH brain inflammation possibly via the sphingosinerelated pathway.
Introduction
Aneurysmal subarachnoid hemorrhage (SAH) is a life-threatening disease carrying the risk of sudden death of 12.4% before receiving medical intervention (Huang and van Gelder, 2002 ) while a majority of deaths occur within the first 48 h post ictus owing to the impact of the initial bleeding (Broderick et al., 1994) . Subarachnoid blood, elevation of intracranial pressure, and reduced cerebral perfusion initiate an acute injury cascade such as microvascular disturbance and inflammatory reaction, leading to early brain injury (EBI), one of the important causes of unfavorable outcomes after SAH (Fujii et al., 2013; Sehba and Bederson, 2006) .
Isoflurane is a volatile anesthetic and a lipophilic molecule (Antkowiak, 2001) . We reported that 2% isoflurane prevented post-SAH neuronal apoptosis and blood-brain barrier (BBB) disruption through sphingosine-related pathway activation (Altay et al., 2012a, b) . Preconditioning with isoflurane was also reported to reduce lipopolysaccharide-induced inflammation in vivo (Plachinta et al., 2003) . However, it remains undetermined whether isoflurane posttreatment prevents brain inflammation in an acute stage of SAH. In this study, thus, we examined effects of post-treatment isoflurane on brain inflammatory markers after SAH in mice and whether the treatment mechanism involved the sphingosine-related pathway, which was verified by using a sphingosine kinase (SphK) inhibitor and a sphingosine-1-phosphate (S1P) receptor-1/3 (S1P1/3) antagonist (VPC23019). 
